Kidney Cancer Research Summit

Even with the increase of immunotherapy utilization to treat patients with advanced renal cell carcinoma, more research is needed to determine in which order to administer it as later lines of therapy.

Therapies that target specific characteristics on kidney cancer cells are showing promise in the space, an expert explained.

With new treatments being explored, it’s an exciting time for patients with kidney cancer, an expert explained.

An expert explained what aspects of a patient’s disease cancer care teams use to determine the best treatment options for patients with clear cell renal cell carcinoma.

Patients with BAP1-mutated renal cell carcinoma who were treated with Lynparza obtained responses with favorable side effect profiles.

An expert gives an overview of up-and-coming treatments for patients with kidney cancer.

Long-term follow-up data showed that Lenvima plus Keytruda continued to show benefit in patients with metastatic kidney cancer.

Immunotherapy combinations tended to improve outcomes for patients with metastatic kidney cancer who go on to receive surgery.

Radiation is an emerging treatment modality in kidney cancer. Research shows that it is effective and helps patients maintain a good quality of life.

Keytruda after nephrectomy improved disease-free survival rates in patients with clear cell renal cell carcinoma regardless of disease risk or stage.

Responses to treatment with Lenvima plus Keytruda for advanced renal cell carcinoma were present regardless of PD-L1 status.

Patients with Medicaid or no insurance may have worse survival outcomes compared with Medicare or private insurance in those with metastatic renal cell carcinoma.